BioNTech touts differences with Moderna in race for cancer vaccines
BioNTech chief strategy officer Ryan Richardson highlighted the differences between his company’s cancer vaccine and another under development by Moderna and Merck, as the companies race each other for a piece of what could be a major new class of products.
Richardson spoke at an investment conference hosted last week by SVB Securities and his comments were described in an analyst note.
BioNTech has several mRNA cancer candidates in the works, including for advanced melanoma, ovarian cancer and non-small cell lung cancer, according to its website. The rivalry with Moderna and Merck is focused around its individualized vaccine, RO7198457 (also known as BNT122), which it calls an individualized Neoantigen Specific immunoTherapy, or iNeST. It’s developing the vaccine with Genentech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.